Zhibin Liang

Dr. Zhibin Liang

Salk Institute for Biological Studies, La Jolla, USA
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LHLing Huang
Ling Huang
DMDaniel B. McClatchy
Daniel B. McClatchy
Pamela MaherPamela Maher
Pamela Maher
ZLZhibin Liang
Zhibin Liang
JDJolene K. Diedrich
Jolene K. Diedrich
ACAntonio Currais
Antonio Currais
Amyloid beta (Aβ) accumulates within neurons in the brains of early stage Alzheimer’s disease (AD) patients. However, the mechanism underlying its toxicity remains unclear. Here, a triple omics approach was used to integrate transcriptomic, proteomic, and metabolomic data collected from a nerve cell model of the toxic intracellular aggregation of Aβ. It was found that intracellular Aβ induces profound changes in the omics landscape of nerve cells that are associated with a pro-inflammatory, metabolic reprogramming that predisposes cells to die via the oxytosis/ferroptosis regulated cell death pathway. Notably, the degenerative process included substantial alterations in glucose metabolism and mitochondrial bioenergetics. Our findings have implications for the understanding of the basic biology of proteotoxicity, aging, and AD as well as for the development of future therapeutic interventions designed to target the oxytosis/ferroptosis regulated cell death pathway in the AD brain.

19 May 2019 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
DSDavid Schubert
David Schubert
DKDevin Kepchia
Devin Kepchia
ZLZhibin Liang
Zhibin Liang
RDRichard Dargusch
Richard Dargusch
JGJoshua Goldberg
Joshua Goldberg
Pamela MaherPamela Maher
Pamela Maher

1 February 2019 in Redox Biology
Verified
Journal Article
Open access
WFWolfgang Fischer
Wolfgang Fischer
ACAntonio Currais
Antonio Currais
ZLZhibin Liang
Zhibin Liang
APAntonio Pinto-Duarte
Antonio Pinto-Duarte
Pamela MaherPamela Maher
Pamela Maher
Alzheimer's disease (AD) is the most frequent age-associated dementia with no treatments that can prevent or slow its progression. Since age is by far the major risk factor for AD, there is a strong rationale for an alternative approach to drug discovery based upon the biology of aging. Phenotypic screening assays that reflect multiple, age-associated neurotoxicity pathways rather than single molecular targets can identify compounds that have therapeutic efficacy by targeting aspects of aging that contribute to AD pathology. And, while the suitability of any single assay can be questioned, a combination of assays can make reliable predictions about the neuroprotective effects of compounds in vivo. Therefore, our lab has developed a combination of phenotypic screening assays that are ideally suited not only to identify novel neuroprotective compounds for the treatment of AD but also their target pathways, thereby potentially providing new therapeutic targets for disease treatment. Using these assays, we screened a large library of extracts from plants with identified pharmacological uses. Analysis of one of these extracts from the plant Yerba santa (Eriodictyon californicum) identified the flavanone sterubin as the active component and further studies showed it to be a potent neuroprotective and anti-inflammatory compound.

9 March 2018 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
ZLZhibin Liang
Zhibin Liang
QLQing X. Li
Qing X. Li

20 November 2020 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ZLZhibin Liang
Zhibin Liang
ACAntonio Currais
Antonio Currais
DSDavid Soriano-Castell
David Soriano-Castell
DSDavid Schubert
David Schubert
Pamela MaherPamela Maher
Pamela Maher

23 May 2016 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
ZLZhibin Liang
Zhibin Liang
BZBei Zhang
Bei Zhang
WSWei Wen Su
Wei Wen Su
Philip WilliamsPhilip Williams
Philip Williams
QLQing X. Li
Qing X. Li